DDInter1346 DDInter1631
A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem]
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Orciprenaline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epinephrine
Orciprenaline {u} (Compound) resembles {v} (Compound) Fenoterol
Orciprenaline {u} (Compound) resembles {v} (Compound) Terbutaline
Orciprenaline {u} (Compound) treats {v} (Disease) asthma
Orciprenaline {u} (Compound) binds {v} (Gene) ADRB2
Orciprenaline {u} (Compound) upregulates {v} (Gene) DDX10
Orciprenaline {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Orciprenaline {u} (Compound) downregulates {v} (Gene) SLC2A6
Orciprenaline {u} (Compound) causes {v} (Side Effect) Dizziness
Orciprenaline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Betamethasone
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine
Orciprenaline (Compound) resembles Fenoterol (Compound)
Orciprenaline (Compound) resembles Terbutaline (Compound)
Orciprenaline (Compound) treats asthma (Disease)
Orciprenaline (Compound) binds ADRB2 (Gene)
Orciprenaline (Compound) upregulates DDX10 (Gene)
Orciprenaline (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Orciprenaline (Compound) downregulates SLC2A6 (Gene)
Orciprenaline (Compound) causes Dizziness (Side Effect)
Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Betamethasone